FDA Clears More Home Health Devices, But Slower in 2026

The Food and Drug Administration authorized more medical devices in the first half of 2026 than it did over the same period last year — but the agency’s review process for many of those devices actually slowed down, according to industry tracking of FDA authorization data. For readers relying on new home health monitoring devices, that combination of more approvals paired with longer waits is worth understanding.

The FDA’s most rigorous review pathway, the Premarket Approval process used for higher-risk devices, took an average of nearly 599 days to complete in the first half of 2026, up from about 402 days over the same period the year before. The more common 510(k) clearance pathway, which covers many of the connected blood pressure monitors, glucose meters, and wearable sensors used in home health monitoring, also slowed slightly — averaging roughly 156 days for a decision, about a week longer than the prior year.

What this means for shoppers: devices marketed as newly cleared or pending FDA clearance this year may be further out from actually reaching store shelves than similar announcements were a year or two ago. It’s a reasonable reason to be a little more patient, and a little more skeptical of marketing that implies a device is imminent, when a new home monitoring product is announced.

At the same time, the FDA has been actively encouraging more home-use medical devices to reach the market through its Home as a Health Care Hub initiative, run out of the agency’s Center for Devices and Radiological Health. The initiative includes an internal Idea Lab that helps device developers think through how a new home-use product will integrate with the other health technology a patient may already be using — a signal that the agency views the home, not just the clinic, as a legitimate and growing site of care.

On the coverage side, Medicare and Medicaid policy continues to lean toward supporting home-based and remotely monitored care rather than away from it. Expanded reimbursement for remote patient monitoring services in recent years has made it more financially viable for physicians to prescribe connected home devices, and current trends suggest support for aging-in-place technology is more likely to expand than contract in the near term. Readers should always confirm current coverage details directly with Medicare or their specific plan, since durable medical equipment and remote monitoring coverage rules can vary and change.

For the self-managing-at-home reader, the practical guidance is simple: a device carrying FDA clearance has cleared a real, if sometimes slow-moving, regulatory bar. When comparing options, it’s worth asking a retailer or manufacturer directly whether a specific product has completed FDA clearance or is still pending — a distinction that matters more given how much longer these reviews are currently taking.